Storied CRISPR gene editing pioneer Editas Medicine $EDIT is in advanced discussions regarding the sale of the preclinical oncology lineup in its pipeline as the biotech works through a makeover of the company, its executive team and the drugs it hopes to take through the clinic, Endpoints News has…
Endpoints NewsThe latest release from Coherent Market Insights titled Androgen Replacement Therapy Market Research Report 2022-2028 (by Product Type, End-User /
With the rise of Merck’s Keytruda and Bayer’s Vitrakvi, which have won accelerated approvals over the last five years for genetically-targeted (rather than tissue-targeted) cancer therapies, the FDA on Monday released new draft guidance to help cancer drug developers try to make similar strides. Bac…
Endpoints NewsIn seven years, a small company has built two programs in immuno-oncology and molecular glues and got itself into a partnership with one of the world’s biggest pharma companies. Now the transatlantic biotech has refilled its coffers. Orionis Biosciences announced Wednesday morning that it finished a…
Endpoints NewsThe FDA’s Obstetrics, Reproductive and Urologic Drugs Advisory Committee of outside experts voted 14-1 to pull Covis Pharma’s controversial preterm birth drug from the market after its confirmatory trial from 2018 failed to confirm the drug’s benefit for babies or mothers. First approved under the a…
Endpoints NewsSpeaking in a Starbucks booth on the sidelines of ASCO in June, Kenneth Galbraith emphasized he wanted what Daiichi Sankyo got for its HER2 breakout drug: a Big Pharma partner that could turn its bispecific into a worldwide med. While not quite the size of an AstraZeneca, Galbraith’s Zymeworks has
Endpoints NewsIn Ratatouille, Remy the rat controls a young cook from his chef’s hat, directing his every move in the restaurant kitchen and helping him make food. Well, messenger RNAs have a Remy too. Cap-binding proteins that bind to one end of RNA sequences direct how they are spliced and translated
Endpoints NewsEverest Medicines said its Covid-19 messenger RNA partner passed a mid-stage test investigating its vaccine against Pfizer and BioNTech’s Comirnaty. Providence Therapeutics’ PTX-COVID19-B was non-inferior to the Big Pharma’s shot in a Phase II trial comparing the vaccines in 18- to 64-year-olds in C…
Endpoints NewsPharma companies may be up in arms with Democrats over their recently passed legislation to allow Medicare to negotiate certain expensive drug prices, but their political action committees (PACs) aren’t showing it, with contributions for both Democrats and Republicans across the country. According t…
Endpoints NewsNew Jersey, United States - Complete study of the Global Benzodiazepines Market is carried
Endpoints News“We estimated that 1.64% of women who never used hair straighteners would go on to develop uterine cancer by the age of 70, but for frequent users, that risk goes up to 4.05%,” study leader Alexandra White of the U.S. National Institute of Environmental Health Safety (NIEHS) said in a statement. Ad…
Endpoints NewsNew Jersey, United States - Verified Market Research announced the publication of a new researc
Endpoints NewsIn February, Oz Azam left Tmunity months after its cell therapy program came to a screeching halt following two patient deaths. At the time, Azam posted on LinkedIn that he was going back to his roots in neuroscience, heading a stealth startup. Tuesday morning, that biotech launched with a $22
Endpoints NewsRight after NGM failed to meet the primary endpoint in a Phase II eye disease trial, one of the Big Pharmas decided to remove a mid-stage candidate from its pipeline. The update was quiet, announced in Roche’s Q3 earnings presentation, where the Swiss pharma said it was removing HtrA1 inhibitor
Endpoints NewsNorth America, March 2022,– – The Asbestosis Treatment Market research report includes an in-sight s
Endpoints NewsMore than 12 years ago, Aveo Oncology vaulted onto Nasdaq with an IPO pitch centered on its lead cancer drug, tivozanib. It took almost a decade, with an FDA rejection, multiple shareholder lawsuits and an SEC investigation along the way, but the biotech finally clinched an approval in the US
Endpoints NewsPfizer is investing in new treatments for celiac disease. The Big Pharma shelled out $35 million in equity for Anokion, a Swiss biotech shooting for a celiac therapy. Anokion intends to use the money to fund Phase II studies for the candidate, known as KAN-101 and acquired in a 2019
Endpoints NewsA small Houston biotech is hitting the brakes on an early clinical trial after a patient’s death. Salarius Pharmaceuticals paused new patient enrollment in a Phase I/II trial after an individual died taking an experimental therapy intended to treat certain sarcomas, the company announced Tuesday. Pa…
Endpoints NewsNew Jersey, United States - The Global Cancer Immunotherapy market is expected to grow at a sig
Sioux City Catholic GlobeNew Jersey, United States - The Global Rheumatic Disorders Drug Market is comprehensively
Sioux City Catholic Globe
